TREATMENT PROTOCOL. A. JBCT is an intensive, milieu-based treatment program that quickly facilitates competency through a combination of group and individual therapy.
TREATMENT PROTOCOL. The Contractor shall be responsible for positively identifying all target species before they are cut or herbicide applied. Failure to do so may incur unnecessary damage done to the DISTRICT, and shall be repaired or replanted at the Contractor’s expense. Any replacement materials are subject to DISTRICT’s approval.
TREATMENT PROTOCOL. The clinical pharmacist will apply nationally recognized evidence-based treatment guidelines, as well as up to date clinical research information when providing diabetes management services. The following treatment guideline(s) and resources will be utilized to help direct the treatment of patients. 2020 American Diabetes Association Standards of Medical Care in Diabetes 2020 Consensus Statement by the Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm From those guidelines, the pharmacist will use the following guiding principles for management of diabetes mellitus. These principles are not binding, and the pharmacist may deviate from what is outlined below based on an individual patient’s clinical situation. If deviations are made, the pharmacist will document rationale in the patient chart.
TREATMENT PROTOCOL. The clinical pharmacist will apply nationally recognized evidence-based treatment guidelines, as well as up to date clinical research information when providing hypertension management services. The following treatment guideline(s) and resources will be utilized to help direct the treatment of patients. 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (ACC/AHA, et al.) 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults – Report from the panel members appointed to the eighth Joint National Committee (JNC 8) American Heart Association – Controlling Hypertension in Adults Contraindications Patients diagnosed with the following will not be eligible for hypertension management by the pharmacist as afforded by this CPA: Patients with stage 4-5 kidney disease Patients on dialysis Pregnancy Patients with LV ejection fraction below 40% {pharmacy/institution may add, remove, or modify any contraindications} Prescribing Provider Consultation The supervising provider will be consulted for the presence of any potentially serious consequences of hypertension or its treatment, including, but not limited to the following: Abnormal vitals Systolic blood pressure > 180 mmHg or < 100 mmHg Diastolic blood pressure > 100 mmHg or < 60 mmHg Heart rate consistently < 55 BPM or > 100 BPM Patient experiences significant side effects/adverse reactions such as significant edema, chest pain, dyspnea, headache, vision changes, dizziness/lightheadedness Suspected undiagnosed secondary causes of hypertension {pharmacy/institution may add, remove, or modify any qualifications} Treatment Goals Antihypertensives will be initiated and/or titrated to the patient-specific blood pressure goal documented in {EHR} by the referring provider. This blood pressure goal will subsequently be documented in the patient’s problem list by the pharmacist. Monitoring TBD
TREATMENT PROTOCOL. The clinical pharmacist will apply nationally recognized evidence-based treatment guidelines, as well as up to date clinical research information when providing hypertension management services. The following treatment guideline(s) and resources will be utilized to help direct the treatment of patients. 2018 Guideline on the Management of Blood Cholesterol (ACC/AHA, et al.) National Lipid Association – Recommendations for Patient-Centered Management of Dyslipidemia Contraindications Patients diagnosed with the following will not be eligible for hyperlipidemia management by the pharmacist as afforded by this CPA: Patients with stage 4-5 kidney disease Patients on dialysis Pregnancy or lactation Patients with New York Heart Association (NYHA) class II-IV heart failure Patients with HIV infection Patients with liver disease or history of cirrhosis Patients with an organ transplant {pharmacy/institution may add, remove, or modify any contraindications} Prescribing Provider Consultation The supervising provider will be consulted for the presence of any potentially serious consequences of hyperlipidemia or its treatment, including, but not limited to the following: Patient experiences an adverse reaction and/or intolerance, including a suspected statin-induced myopathy Abnormal labs Baseline triglycerides above 400 mg/dL Baseline LDL-C < 70 mg/dL or > 190 mg/xX XXX or ALT elevated on 2 or more occasions {Pharmacy/institution may add, remove, or modify any qualifications} Treatment Goals Antihyperlipidemic agents will be initiated and/or titrated to the patient-specific cholesterol goals documented in {EHR} by the referring provider. These goals will subsequently be documented in the patient’s problem list by the pharmacist. Monitoring The pharmacist will place an order for a repeat lipid panel within 4-12 weeks of initiating therapy or 4-6 weeks after modifying therapy. Additionally, the pharmacist will follow-up with the patient within 4 weeks of medication initiation or adjustment to assess tolerance, adherence, and therapeutic response.
TREATMENT PROTOCOL. CTTC will provide the list of Objectives and Goals, the Calmare(R) Tutorial & Study Guide, Calmare(R) Treatment Protocol and the User's Manual for the MC-5A, or equivalent Calmare(R) device. Upon successful completion the participant will be awarded a Calmare(R) Scrambler MC-5A User Certificate. CTT8K41924 SCHEDULE 12 COUNTRY/ COUNTRIES IN ASSIGNED TERRITORY ITALY MALTA CTT8K41925 SCHEDULE 13 PRICING
TREATMENT PROTOCOL. FFF shall be responsible for obtaining a Treatment Protocol, as defined in section 1.26, under the FFF IND and in accordance with the provisions of this section 5.1.
TREATMENT PROTOCOL. FFF shall prepare a treatment protocol ("Treatment Protocol") in consultation with and information provided by Omrix and in accordance with 21 CFR Section 312.35(a) to use the Investigational Drug to treat patients with primary immune deficiency who are not enrolled as subjects in the Clinical Trials. FFF has been engaged in discussions with the FDA regarding the Treatment Protocol and shall continue to be responsible for negotiating the terms of the Treatment Protocol with the FDA. FFF shall prepare the Treatment Protocol in time for FFF to submit it to the FDA immediately after initiation of the Phase 2 Clinical Trial with the goal of obtaining approval during or immediately after the conclusion of the Phase 2 Clinical Trial. FFF shall be the sponsor of the Treatment Protocol and shall submit the Treatment Protocol to the FDA under the FFF IND. In addition, FFF will provide Omrix with an electronic copy of the packaging material which will be used in the Treatment Protocol consistent with all FDA requirements.
TREATMENT PROTOCOL. Omrix shall provide to FFF in a timely manner any information in Omrix's possession about the Investigational Drug that is necessary for FFF to prepare the Treatment Protocol, including without limitation technical, pre-clinical, clinical, and information regarding the Manufacturing Specifications. Omrix shall provide FFF with feedback in a timely manner on drafts of the Treatment Protocol.
